Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
PharmaDrug Receives Positive Results for DMT-Analogue Program to Treat Glaucoma
- PharmaDrug receives encouraging potency data for candidate DMT-analogue molecules designed to treat primary open angle glaucoma
- Terasaki Institute advances PharmaDrug’s candidate DMT-analogue molecules into next phase of potency/kinetics study
Filament Health and ATMA Journey Centers Announce Licensing Agreement
“The selection of our natural psilocybin drug candidate for ATMA’s future clinical trials is a validation of both our product and the ease of working with Filament Health,” said Filament Chief Executive Officer, Benjamin Lightburn. “ATMA is a leader in psychedelic-assisted psychotherapy and we are thrilled that they will be using our product.”
Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program
The company is pleased to announce that it has awarded a contract to Zhejiang Ausun Pharmaceutical CO, LTD of China to begin the manufacturing of a cGMP supply of its repurposed drug candidate NP-251 (“Repirinast”) and has initiated a new chronic kidney disease (“CKD”) research program.
Mycrodose Therapeutics Granted DEA and FDA Approval to Cultivate Psilocybin Mushrooms in the United States
DEA approval allows Mycrodose Therapeutics to become the first vertically integrated US Pharmaceutical company utilizing psilocybin-based psychedelic medicine. Approval also allows Mycrodose the ability to deepen its control on the US supply-chain, better protect their development of and expansion of Intellectual Property and reduce R&D expenditures by millions of dollars annually.
PharmaTher Receives U.S. Patent For Ketamine
The company announced that it’s been granted a new patent for the combination of FDA-approved ketamine and PharmaTher’s proprietary betaine anhydrous (“KETABET™”).
Entheon Biomedical Announces EBIQ-101 First-Patient Dose
“We are pleased to report that the first patient has been dosed in EBIQ-101, a study using electroencephalography (EEG) to observe variability in neurological activity in patients prior to, during, and after ketamine treatments. “
